A real-world retrospective single-center study to determine efficacy and toxicity in patients treated with Immunotherapy in various solid malignancies
Latest Information Update: 04 Jul 2022
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Lung cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 30 Jun 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology